Northeast Pharmaceutical announced that from April 9, 2025 to April 15, 2025, Jiangxiangda Steel Group Co., Ltd. increased its holdings of the company's shares by a total of 1,517,500 shares through centralized bidding transactions at the Shenzhen Stock Exchange, accounting for 0.106% of the company's total share capital. After this increase in holdings, the controlling shareholders of the company and their co-actors held a total of 786 million shares of the company, accounting for 55.00% of the company's total share capital. In accordance with the “Notice Concerning Matters Relating to Establishing Stock Repurchase and Increase Refinancing” issued by the People's Bank of China, the General Administration of Financial Supervision, and the China Securities Regulatory Commission, Fangda Steel received special loan support to increase stock holdings. The loan amount was RMB 108 million. The loan period was 36 months, and the loan interest rate was 2.25%.

Northeast Pharmaceutical announced that from April 9, 2025 to April 15, 2025, Jiangxiangda Steel Group Co., Ltd. increased its holdings of the company's shares by a total of 1,517,500 shares through centralized bidding transactions at the Shenzhen Stock Exchange, accounting for 0.106% of the company's total share capital. After this increase in holdings, the controlling shareholders of the company and their co-actors held a total of 786 million shares of the company, accounting for 55.00% of the company's total share capital. In accordance with the “Notice Concerning Matters Relating to Establishing Stock Repurchase and Increase Refinancing” issued by the People's Bank of China, the General Administration of Financial Supervision, and the China Securities Regulatory Commission, Fangda Steel received special loan support to increase stock holdings. The loan amount was RMB 108 million. The loan period was 36 months, and the loan interest rate was 2.25%.